title: LEP and LEPR polymorphisms in non-Hodgkin lymphoma risk: a systematic review and pooled analysis.
abstract: OBJECTIVE
  The purpose of this systematic meta-analysis was to evaluate the association between leptin (LEP) and leptin receptor (LEPR) gene polymorphisms and non-Hodgkin lymphoma (NHL) risk.
  
  
  METHODS
  All studies published up to July 2014 on the association between LEP and LEPR polymorphisms and NHL risk were identified by searching PubMed, Web of Science, EMBASE, and Google Scholar. Odds ratios (ORs) with 95% confidence intervals (CIs) for LEP and LEPR polymorphisms and NHL were calculated with fixed-effects and random-effects models.
  
  
  RESULTS
  LEP G2528A polymorphism was associated with increased, yet not statistically significant risk of NHL (homozygote comparison, OR=1.27, 95% CI=1.01-1.60, p=0.63; heterozygote comparison, OR=1.13, 95% CI=0.86-1.49, p=0.14; dominant model, OR=1.18, 95% CI=0.99-1.41, p=0.21; recessive model, OR=1.18, 95% CI=0.97-1.43, p=0.78; additive model, OR=1.14, 95% CI=1.01-1.28, p=0.52). Significant decrease of NHL risk was found in LEP A19G polymorphism, while no links were detected with the LEPR polymorphisms studied. In subgroup analysis, the pooled results showed that LEP A19G polymorphism was associated with decreased risk of follicular lymphoma (FL) (homozygote comparison, OR=0.56, 95% CI=0.37-0.85, p=0.69). However, no evidence of a significant association was observed in diffuse large B-cell lymphoma (DLBCL) for variant genotypes of all single nucleotide polymorphisms (SNPs).
  
  
  CONCLUSIONS
  LEP G2548A polymorphism contributes to NHL susceptibility. Also, our results provide evidence that LEP A19G polymorphism is associated with decreased risk of NHL, especially in FL. Further large-scale and well-designed studies are needed to confirm this association.
authors.affiliation: 1Department of Orthopedics, Shanghai Tenth People's Hospital, Tongji University, School of Medicine, Shanghai, China.
authors.forename: Hai-Yan
authors.initials: HY
authors.lastname: Lin
authors.forename: Hui
authors.initials: H
authors.lastname: Shi
authors.forename: Chun-Yan
authors.initials: CY
authors.lastname: Li
authors.forename: Quan-Chi
authors.initials: QC
authors.lastname: Chen
authors.forename: Tian-Bao
authors.initials: TB
authors.lastname: Huang
authors.forename: Peng-Cheng
authors.initials: PC
authors.lastname: Liu
authors.forename: Lie-ming
authors.initials: LM
authors.lastname: Lou
mesh_terms: D016009:Chi-Square Distribution; D020022:Genetic Predisposition to Disease; D006579:Heterozygote; D006720:Homozygote; D006801:Humans; D020738:Leptin / Q000235:genetics*; D008228:Lymphoma, Non-Hodgkin / Q000175:diagnosis / Q000208:ethnology / Q000235:genetics* / Q000517:prevention & control; D016017:Odds Ratio; D020641:Polymorphism, Single Nucleotide; D065840:Protective Factors; D054411:Receptors, Leptin / Q000235:genetics*; D012307:Risk Factors
chemical_list: C515448:LEPR protein, human; D020738:Leptin; D054411:Receptors, Leptin